Business Wire

ORTEC

16.1.2024 15:31:30 CET | Business Wire | Press release

Share
ORTEC Partners with Global Investment Firm Battery Ventures to Accelerate Its Growth Ambitions

ORTEC, a global provider of decision support software and data science capabilities, is pleased to announce a partnership with investment firm Battery Ventures to accelerate its growth ambitions. This strategic partnership, including a significant investment by Battery, marks a key moment in ORTEC’s existence and positions the company to increase its impact on customers and in core markets globally. With this partnership, ORTEC will be able to further strengthen its leadership position in the US and Europe in the field of supply chain, workforce-management and data science & consulting.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240116805637/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Michael van Duijn (ORTEC CEO) and Zak Ewen (Partner Battery Ventures) (Photo: Business Wire)

Improving the world through data and mathematics

The ORTEC journey started in the early 1980s, when a few passionate Dutch students wanted to show the world the value of mathematics by creating long-term sustainable growth for organizations and society. Specifically, the company’s initial consulting business helped customers leverage data and mathematical models to solve operational problems. Over time, the company developed commercial products that help large enterprises address complex logistical challenges such as last-mile fleet dispatch and route planning; pallet-load planning and optimization; and advanced workforce scheduling and resource planning.

Now, more than 40 years later, ORTEC delivers solutions to over 1,200 customers worldwide to improve business results and make a positive impact on the world. Customers include ASML, Heineken, Coca-Cola Enterprises, Procter & Gamble, Shell, Waitrose, Albert Heijn, G4S, Sodexo and Tesco.

In partnership with Battery, going forward, ORTEC will offer products and services through three new divisions that focus on logistics and routing solutions, workforce-management solutions, and data science and consulting. Battery, which was founded in 1983, is a longtime, global software investor that has made more than 500 investments over the last four decades.

“We are very pleased that Battery Ventures joins ORTEC as a strategic partner. With their knowledge, experience, and network, we can further drive innovation, expand our market reach and create additional impact for our customers,” said Michael van Duijn, ORTEC’s chief executive. “I am proud of the great company we are today and the amazing group of talented employees that create impact for our customers day in and day out. It makes me excited that with this partnership, we have the ingredients to make a more positive impact on the world.”

Shared commitment to long-term growth

The agreement between ORTEC and Battery Ventures highlights a shared commitment to drive innovation, deliver exceptional value to customers, and achieve long-term impact growth. Both parties are confident that the partnership will pave the way for ORTEC to expand its strong position as a leading provider of optimization technology built to solve complex operational challenges in an increasingly data-driven world.

“We’ve gotten to know ORTEC and its founding team over a period of more than 10 years, and during that time we’ve watched the business transform from a consulting-led business into a commercial software company serving the world’s most sophisticated and complex enterprises,” said Zak Ewen, a Battery partner based in London, who joins ORTEC’s board. “Now we’re excited to formally partner with Michael, Aart, Gerrit and the rest of the team to further accelerate the company’s mission.”

Moving forward, ORTEC founders Aart van Beuzekom and Gerrit Timmer remain part of the board and will continue to take care of ORTEC and its future.

About ORTEC

For more than 40 years ORTEC has been supporting many of the world’s best-run organizations to make better data-driven decisions. Our decision support software and data science capabilities enable our customers to improve their business results and make a positive impact on the world. With our 1,000 employees across 13 countries, we help over 1,200 leading customers worldwide to make better choices in an ever-changing environment. Discover more at www.ortec.com.

About Battery Ventures

Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, online marketplaces, healthcare IT and industrial technology. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from six strategic locations: Boston; San Francisco and Menlo Park, Calif.; Herzliya, Israel; London; and New York. Follow the firm on X @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240116805637/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release

Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri

AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release

From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi

Avanzanite Expands French Operations and Appoints Constance Sabbagh as General Manager24.3.2026 07:00:00 CET | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring rare disease medicines to patients in every European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323639110/en/ Constance Sabbagh, General Manager, France “France is essential to Avanzanite’s European vision,” said Adam Plich, Co-founder and CEO of Avanzanite. “With its leadership in rare disease policy through its National Rare Disease Plans, care networks and scientific innovation, France is one of the most significant healthcare

HJS Foundation Releases JEP Protocol & HJS Framework: The "Black Box" for AI, Enabling Verifiable Human Oversight24.3.2026 04:36:00 CET | Press release

HJS Foundation (Human Judgment Systems Foundation) today released two complementary solutions: the Judgment Event Protocol (JEP) and the Human Judgment Structure (HJS) framework. As a minimalist open standard, JEP generates tamper-proof records of AI decision accountability, just like an aircraft black box; HJS embeds human judgment logic into AI operation processes — together, they transform "human oversight" from a regulatory requirement into a verifiable technical fact, providing an optional technical solution for AI accountability. How to prove that AI decisions (such as loan approvals, medical diagnoses, border screenings, etc.) have undergone human review? JEP generates immutable audit trails of human intervention through four cryptographic primitives — Judge, Verify, Delegate, Terminate; HJS builds a controllable and accountable system to prevent risks such as AI drift and ensure that human judgment guides AI operations. Current systems rely on alterable post-hoc documentation,

Power Integrations Extends Flyback Topology to Enable 440 W, Offering Simpler Alternatives to Resonant Power Designs23.3.2026 22:45:00 CET | Press release

New TOPSwitchGaN ICs more than double power output, reducing system cost, complexity, and design time APEC 2026 – Power Integrations (NASDAQ: POWI), the leader in high-voltage integrated circuits for energy-efficient power conversion, today introduced a breakthrough in flyback topology extending the power range of flyback converters to 440 W—well beyond the limits that traditionally required more complex resonant and LLC topologies. The new TOPSwitchGaN™ flyback IC family unites the company’s groundbreaking PowiGaN™ technology with its iconic TOPSwitch™ IC architecture, reducing complexity, eliminating heat sinks in many cases, shortening design time, improving manufacturability, and lowering total system cost. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323686299/en/ The new TOPSwitchGaN™ flyback IC family extends the power range of flyback converters to 440 W—well beyond the limits that traditionally required more co

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye